Dr. Huiman X Barnhart's lab at Duke University focuses on understanding and addressing drug-induced liver injuries (DILI). The lab plays a critical role in the Drug-Induced Liver Injury Network, where they gather and analyze clinical data to identify genetic factors that contribute to liver damage from medications and supplements. The ultimate goal is to develop safer drugs and supplements by discovering predictive biomarkers and understanding the underlying mechanisms of liver injury.

Dr. Xiaofei Wang's lab focuses on enhancing clinical trials by utilizing real-world data (RWD) while addressing potential biases that could affect treatment evaluations. The lab aims to create new statistical methods and frameworks to integrate RWD effectively, ensuring that clinical trial results are robust and reliable. Additionally, they prioritize sharing these innovative approaches with industry and academic researchers to promote better regulatory practices in drug development.

Dr. Andrew S. Allen's lab at Duke University focuses on understanding how noncoding genetic variations affect gene regulation and contribute to diseases. The research aims to develop innovative tools and statistical methods for annotating these variations, which are often overlooked but play critical roles in health and disease. By integrating machine learning approaches with genomic data, the lab seeks to improve predictions about how genetic variations influence patient outcomes.

Dr. Cliburn C Chan's lab at Duke University focuses on developing computational models to better understand how the immune system responds to influenza viruses. By analyzing various datasets, the lab aims to create predictive models of antibody responses, which could lead to more effective vaccines against seasonal and pandemic influenza. They combine techniques from biostatistics and immunology to simulate how antibodies protect against infection, ultimately helping to advance vaccine development.

Dr. Gregory E. Crawford leads a research lab at Duke University focused on the complex interactions of multiple genes in health and diseases. Their work aims to develop innovative technologies that allow researchers to manipulate the expression of many genes simultaneously, moving beyond the traditional single-gene approach in gene therapy and disease modeling. The lab strives to enhance our understanding of how multigenic factors contribute to various conditions, ultimately paving the way for more effective treatments.

Dr. Bruce R. Donald's lab at Duke University focuses on using advanced computational methods and experimental techniques to study and design proteins. The lab aims to uncover the three-dimensional structures of proteins, which are crucial for understanding diseases and designing new drugs. By developing novel algorithms and conducting in vitro and in vivo experiments, the research seeks to tackle challenges in drug resistance and create innovative therapeutics to target previously undruggable proteins.

Dr. Anru Zhang's lab focuses on improving the assessment and treatment of sepsis, a life-threatening condition that arises from the body's response to infection. Using advanced statistical techniques, particularly tensor methods, the lab analyzes electronic health record (EHR) data to identify patient characteristics and outcomes more accurately. Their work aims to create innovative tools that enhance clinical decision-making and ultimately improve patient care in hospitals.